sorafenib / Generic mfg. - LARVOL DELTA

New thought and strategy of liver cancer immunotherapy (AACR 2026) - "Approximately 17% liver cancer patients responded to monotherapy of pembrolizumab and 20% responded to nivolumab. A combination of nivolumab and ipilimumab increased the response rate to 30% in HCC. Simultaneous blockade of PD-L1 and VEGF signaling using atezolizumab and bevacizumab achieved better overall and progression-free survival than sorafenib in HCC.Our previous data showed that monotherapy with anti-PD-L1 antibody exhibited no inhibitory effect in primary liver cancer driven by classical oncogenes in mice...The data suggest that it is the tumor microenvironment, rather than the tumor cells, that determine the response to immunotherapy.We have also found that the polyIC+antiPD-L1 combination exhibited more potent anti-tumor effect than antiPD-L1+antiVEGFA. Further, we demonstrate that a monotherapy of liver-targeting lipid nanoparticles that encapsulate polyIC (polyIC-LNP) is sufficient to suppress both primary and metastasized liver tumor progression in mouse..."

IO biomarker • Liver Cancer • Oncology • Solid Tumor

Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial. (PubMed, Int J Cancer) - "For all definitions of early progression/treatment failure, the risk was either significantly lower with atezolizumab plus bevacizumab than with sorafenib, or there were no differences. Atezolizumab plus bevacizumab treatment is unlikely to cause significant HPD."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • AFP

IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma (ESMO 2025) - P3 | "The IMbrave150 phase 3 study showed that the combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF antibody bevacizumab (atezo/bev) extend survival compared to sorafenib in 1L treatment of advanced and intermediate HCC failing/unsuited for TACE. Conclusions The first IA provides important insights into the efficacy of atezo/bev vs. TACE in intermediate stage HCC. Based on these findings, the trial is progressing to the 2nd IA at 66% information time (169 events)."

Clinical • Late-breaking abstract • P3 data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology

Liver Stiffness Measured by Vibration-Controlled Transient Elastography Predicts Hepatic Decompensation in Patients with Hepatocellular Carcinoma Receiving Systemic Treatments. (PubMed, Liver Cancer) - "Hepatic decompensation (HD) following systemic treatment, including atezolizumab + bevacizumab (Atezo/Bev) and tyrosine kinase inhibitors (TKIs), is a critical prognostic event in advanced hepatocellular carcinoma (HCC)...Of the 396 patients, 176 received Atezo/Bev, while 45 and 175 received lenvatinib and sorafenib, respectively...LSM by VCTE predicts HD following systemic treatment in advanced HCC. In patients with high LSM, Atezo/Bev increases HD risk, warranting careful treatment selection."

Clinical • Journal • Cardiovascular • Hematological Disorders • Hepatocellular Cancer • Liver Failure • Oncology • Solid Tumor • Thrombosis

IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma. (ASCO-GI 2026) - "The IMbrave150 phase 3 study demonstrated that combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF antibody bevacizumab (atezo/bev) extends survival compared to sorafenib in first-line treatment of advanced and intermediate stage HCC failing/unsuited for TACE which has led to its approval in this setting. The results of the first IA provide important insights into the efficacy of atezo/bev vs. TACE in intermediate stage HCC and suggest a superiority of systemic therapy compared to TACE in regard to TTFS. Based on these findings, the trial is progressing to the second IA at 66% information time (169 events)."

Clinical • P3 data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Two integrative molecular subtypes of hepatocellular carcinoma with predictive therapeutic potential: Toward liquid biopsy-guided precision medicine (AACR 2026) - "In the IMbrave150 cohort, the Immune subtype showed superior survival outcomes to atezolizumab-bevacizumab (p < 0.0001). Conversely, the METabolic subtype was associated with 100% recurrence after sorafenib treatment, suggesting potential benefit from MET inhibitors after sorafenib failure...Additionally, our study suggests the Immune subtype is an optimal candidate for immunotherapy combined with anti-VEGF(R) agents. Further validation in larger, prospective cohorts is warranted to translate these findings into clinical practice."

Biopsy • IO biomarker • Liquid biopsy • Hepatocellular Cancer • Oncology • Solid Tumor • CD8 • CTNNB1 • IL6R • IL6ST • MB • TP53

First-line Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in Egyptian patients with unresectable hepatocellular carcinoma: a retrospective real-world study (EASL 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy and safety of first-line immunotherapy and targeted therapy in advanced HCC: a network meta-analysis with subgroup analysis based on HBV and HCV infection. (PubMed, Front Immunol) - "In the overall population, regimens with significant OS advantage over sorafenib included sintilimab plus bevacizumab biosimilar (HR = 0.57, 95% CrI 0.43-0.75), camrelizumab plus rivoceranib (HR = 0.62, 0.48-0.79), and atezolizumab plus bevacizumab (HR = 0.66, 0.51-0.84). For PFS, top-ranked combinations were camrelizumab plus rivoceranib (HR = 0.52, 0.41-0.66), anlotinib plus penpulimab (HR = 0.53, 0.41-0.68), lenvatinib plus pembrolizumab (HR = 0.55, 0.44-0.68), and sintilimab plus bevacizumab biosimilar (HR = 0.56, 0.45-0.69)...Regarding safety, tislelizumab (RR = 0.42, 0.33-0.52) and nivolumab (RR = 0.45, 0.36-0.56) were associated with the lowest incidence of AEs≥3...In non-viral HCC, the STRIDE regimen (single priming dose tremelimumab plus durvalumab) was the only regimen to significantly improve OS (HR = 0.75, 0.59-0.96)...This etiology-stratified evidence..."

Clinical • Journal • Retrospective data • Review • Hepatitis C • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Viral Hepatitis and Immunotherapy Outcome in Advanced Hepatocellular Carcinoma: A Comprehensive Umbrella Review of 15 Meta-Analyses. (PubMed, Crit Rev Oncol Hematol) - "ICI-based combinations are effective first-line therapy for unresectable/advanced HCC. Viral hepatitis status, particularly HBV, may be associated with larger relative benefit than nonviral etiology, but subgroup and real-world findings require cautious interpretation. This synthesis clarifies the strength and limitations of current evidence and identifies priority areas for prospective validation, with direct implications for treatment selection as nonviral HCC becomes more prevalent."

Journal • Review • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Design, synthesis, and mechanistic study of bispecific small molecules-based phenyl pyrazolopyrimidinone scaffold as dual-targeting VEGFR and PD-L1 immune checkpoint in hepatocellular carcinoma. (PubMed, Bioorg Chem) - "Among the synthesized series, compound 8g exhibited the highest potency, with IC₅₀ values of 3.93 μM, 9.56 μM, and 6.30 μM against HepG2, PC-3, and HCT-116, respectively, surpassing the reference drugs doxorubicin (4.50 μM against HepG2) and sorafenib (9.18 μM against HepG2). Mechanistically, 8g demonstrated strong inhibition of VEGFR2 (IC₅₀ = 0.38 μM), but it outperformed PD-L1 inhibition compared to Bavencio (IC₅₀ = 134.41 pg/mL and 217.74 pg/mL, respectively)...In silico molecular docking and dynamic simulation assisted data strongly correlated with the experimental approach that compound 8g exerts multi-targeted anticancer activity via VEGFR2 and PD-L1 inhibition. In conclusion, 8g is a promising candidate recommended for further therapeutic development."

Journal • Colorectal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Oncology • Prostate Cancer • Solid Tumor • BAX • BCL2 • CASP3

Thiadiazole-Derived VEGFR-2 Inhibitors: From Design to Anticancer Evaluation. (PubMed, Chem Biol Drug Des) - "Among them, compound 9b showed the strongest VEGFR-2 inhibition (IC50 = 0.030 ± 0.001 μM), outperforming the reference drug Sorafenib...Extensive in silico studies-including molecular docking, 200 ns molecular dynamics simulations, interaction mapping, principal component analysis of trajectories, and free energy landscape analysis-confirmed that 9b binds stably and efficiently within the VEGFR-2 active site. Overall, these results highlight compound 9b as a promising VEGFR-2-targeted antiangiogenic agent with potent enzymatic and cellular activity, favorable selectivity, and mechanistic validation through combined experimental and computational approaches."

Journal • Breast Cancer • Oncology • Solid Tumor • BCL2 • CASP3

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "Anlotinib plus penpulimab significantly improved progression-free survival and overall survival versus sorafenib in unresectable HCC and might be a new first-line option. These findings require verification in other regions of the world."

Journal • P3 data • Cardiovascular • Hepatocellular Cancer • Hepatology • Hypertension • Liver Failure • Oncology • Solid Tumor • AFP

Cost-Effectiveness Analysis of Anlotinib Plus Penpulimab Versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma in China. (PubMed, Clin Drug Investig) - "Our study suggests that anlotinib combined with penpulimab represents a cost-effective first-line treatment option for patients with uHCC from the perspective of the Chinese healthcare system. These results provide critical evidence to inform clinical practice and healthcare reimbursement policy."

HEOR • Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Short and Long Non-Coding RNAs in Renal Cell Carcinoma. (PubMed, Noncoding RNA) - "Moreover, the manuscript discusses ncRNA-mediated mechanisms of resistance to targeted therapies such as sunitinib, sorafenib, and axitinib, emphasizing regulatory networks involving miRNA targets, lncRNA-miRNA sponging, RNA-binding proteins, extracellular vesicle transfer, and epigenetic modulation. Emerging therapeutic opportunities are also addressed, including strategies aimed at inhibiting oncogenic ncRNAs or restoring tumor-suppressive ncRNAs to enhance drug sensitivity and improve patient stratification."

Journal • Review • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Impact of poly(rC)-binding protein 2 (PCBP2) on the malignant phenotype of cholangiocarcinoma. (PubMed, Biochem Pharmacol) - "Silencing PCBP2 in CCA cells did not alter the response to anti-CCA drugs (cisplatin, oxaliplatin, gemcitabine, 5-fluorouracil, and sorafenib) but reduced cell viability and proliferation, impaired colony formation, and inhibited migration. Electrophoretic mobility shift assay (EMSA) demonstrated that PCBP2 binds to the DHRS3 3'UTR, suggesting a role for PCBP2 in the post-transcriptional regulation of its target genes. In conclusion, PCBP2 promotes the malignant phenotype in CCA, highlighting its potential as a target for the development of future pharmacological treatments for patients with this cancer."

Journal • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • MEX3A • NRP2 • PCBP2 • PCGF2

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. (PubMed, Hepatology) - "Participants who experienced imAEs with STRIDE had a numerical improvement in OS versus those who did not, which was not observed for durvalumab. Long-term OS with STRIDE was observed regardless of imAEs. Most imAEs were low grade, manageable, and occurred in the first 3 months after treatment initiation. Results continue to support the benefits of STRIDE in a diverse population that reflects unresectable HCC globally."

Adverse events • Clinical • Journal • Monotherapy • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor

Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW. (ASCO-GI 2026) - P3 | "After 4 years of follow-up, 1L NIVO + IPI continued to show sustained efficacy benefit vs LEN/SOR in unresectable HCC and manageable safety with no new concerns. These results continue to support NIVO + IPI as a standard-of-care treatment in these patients. aPer BICR."

Clinical • Late-breaking abstract • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway. (PubMed, Front Oncol) - "The combination strategy provides a novel potential approach for improving the therapeutic efficacy of sorafenib and overcoming both intrinsic and acquired sorafenib resistance in HCC. The main limitations of this study are the lack of RT-PCR verification and further detection of downstream apoptotic effector molecules, which need to be explored in future research."

IO biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • BAX • BCL2

Study on the effect of Ursolic acid on liver cancer cells using z-vad-fmk and ROS inhibitors. (PubMed, Cytotechnology) - "UA has a significant inhibitory effect on proliferation and promotes apoptosis in liver cancer cells."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

N2013-02: Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: New Approaches to Neuroblastoma Therapy Consortium | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Neuroblastoma • Oncology • Solid Tumor

Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study. (PubMed, Oncologist) - "In this long-term post-hoc update of the TIVO-3 trial, we show that in CPI-resistant mRCC, the PFS benefit of tivozanib over sorafenib is accompanied with improved OS data, although not statistically significant, and durable responses."

Checkpoint inhibition • Clinical • Journal • P3 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. (PubMed, Lancet) - P3 | "Nivolumab plus ipilimumab showed a significant overall survival benefit versus lenvatinib or sorafenib and manageable safety in patients with previously untreated unresectable hepatocellular carcinoma. These results support nivolumab plus ipilimumab as a first-line treatment in this setting."

Journal • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor • AFP

A phase I, multi-center, open-label, dose escalation and expansion study of AST-201 in patients with GPC3-positive advanced solid tumors (ESMO 2025) - P1 | "In preclinical models of GPC3-positive liver and lung cancers, AST-201 exhibited potent, selective cytotoxicity and superior tumor suppression compared to free gemcitabine and sorafenib. Legal entity responsible for the study Aptamer Sciences, Inc. Funding Aptamer Sciences, Inc."

Clinical • Metastases • Hepatocellular Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • GPC3

TROPHY-15: MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib (clinicaltrials.gov) - P3 | N=594 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation • FLT3